ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
CervoMed Inc

CervoMed Inc (CRVO)

19.92
-1.48
(-6.92%)
Closed 23 June 6:00AM
19.92
0.01
(0.05%)
After Hours: 9:29AM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
19.92
Bid
4.77
Offer
31.86
Volume
254,435
19.15 Day's Range 22.39
4.22 52 Week Range 26.3789
Market Cap
Previous Close
21.40
Open
21.40
Last Trade
50
@
19.65
Last Trade Time
Financial Volume
US$ 5,175,859
VWAP
20.3426
Average Volume (3m)
29,184
Shares Outstanding
8,253,741
Dividend Yield
-
PE Ratio
-16.72
Earnings Per Share (EPS)
-0.26
Revenue
7.15M
Net Profit
-2.17M

About CervoMed Inc

Diffusion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The company's lead product candidate is tran... Diffusion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The company's lead product candidate is trans sodium crocetinate (TSC), which is used for the treatment of glioblastoma multiforme (GBM) and metastatic brain cancer. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
CervoMed Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CRVO. The last closing price for CervoMed was US$21.40. Over the last year, CervoMed shares have traded in a share price range of US$ 4.22 to US$ 26.3789.

CervoMed currently has 8,253,741 shares in issue. The market capitalisation of CervoMed is US$36.32 million. CervoMed has a price to earnings ratio (PE ratio) of -16.72.

CRVO Latest News

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

- Topline data expected in December 2024 - - Phase 2b design optimized for success; clear path to market in this high value indication expected with positive result - BOSTON, June 11, 2024...

CervoMed to Appoint William Elder as Chief Financial Officer

BOSTON, May 20, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced the...

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

- CervoMed on track to complete enrollment in 2Q 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies (DLB); topline data expected in 4Q...

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

- Announced private placement of up to $149.4 million led by RA Capital Management with participation from Armistice Capital, Special Situations Funds and Soleus Capital; pro forma cash and cash...

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

Funding from new investors, including RA Capital Management, Armistice Capital, Special Situations Funds and Soleus Capital $50 million financing upfront with up to an additional $99.4 million...

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

- Neflamapimod led to significant reduction compared to placebo in plasma levels of glial fibrillary acidic protein (GFAP) - Neflamapimod effects on GFAP correlated to clinical outcomes assessed...

CervoMed to Participate in the BIO CEO and Investor Conference

BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that...

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

-Integrated summary of all previously published Phase 2a clinical results, together with the first peer reviewed publication of EEG and MRI results, substantially derisk the ongoing RewinD-LB...

Period †ChangeChange %OpenHighLowAvg. Daily VolVWAP
10.412.1014864172219.5122.5717.157107820.08951381CS
41.216.4671298770718.7122.5717.154244719.61968686CS
12-1.64-7.6066790352521.5625.9217.152918421.63506323CS
2612.93184.9785407736.9926.37895.852815718.2095634CS
526.4247.555555555613.526.37894.223452412.32829436CS
1566.4247.555555555613.526.37894.223452412.32829436CS
2606.4247.555555555613.526.37894.223452412.32829436CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ME1OEMelodiol Global Health Ltd
AUD 0.006
(100.00%)
34
K2FK2fly Limited
AUD 0.1825
(82.50%)
2.49M
PRXProdigy Gold NL
AUD 0.003
(50.00%)
100.11k
ARVOCArtemis Resources Limited
AUD 0.003
(50.00%)
1.05M
MTBMount Burgess Mining Nl
AUD 0.0015
(50.00%)
5.38k
BNROBulletin Resources Limited
AUD 0.001
(-66.67%)
100k
FRSOAForrestania Resources Ltd
AUD 0.006
(-57.14%)
26k
GGEOAGrand Gulf Energy Limited
AUD 0.001
(-50.00%)
2.18M
D2OOADuxton Water Limited
AUD 0.021
(-47.50%)
4.5k
CT1Constellation Technologies Limited
AUD 0.002
(-33.33%)
50.02k
REDRed 5 Limited
AUD 0.4175
(3.09%)
135.31M
BGLBellevue Gold Limited
AUD 1.835
(-1.34%)
81.32M
NICNickel Industries Ltd
AUD 0.825
(-3.23%)
62.62M
S32South32 Limited
AUD 3.74
(1.77%)
56.22M
CXOCore Lithium Ltd
AUD 0.0855
(-6.04%)
56.06M

CRVO Discussion

View Posts